SoftBank Group’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$34.4M Hold
20,451,570
0.19% 17
2026
Q1
$27M Hold
20,451,570
0.24% 18
2025
Q4
$38.2M Hold
20,451,570
0.25% 17
2025
Q3
$26.2M Hold
20,451,570
0.1% 20
2025
Q2
$25.4M Hold
20,451,570
0.1% 20
2025
Q1
$24.1M Hold
20,451,570
0.08% 16
2024
Q4
$37.4M Buy
+20,451,570
New +$39.9M 0.16% 15

Other funds holding PACB

SoftBank Group's PACB Position: Q2 2026 in Review

SoftBank Group held its Pacific Biosciences (PACB) position steady in Q2 2026 at 20,451,570 shares worth $34.4M. The position accounts for 0.19% of the portfolio, ranked #17.

SoftBank Group first reported a position in PACB in Q4 2024 and has held it in 7 quarters since. The position peaked at $38.2M in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • SoftBank Group held 20,451,570 shares of Pacific Biosciences worth $34.4M as of Q2 2026.
  • SoftBank Group left its Pacific Biosciences share count unchanged in Q2 2026.
  • Pacific Biosciences made up 0.19% of SoftBank Group's portfolio in Q2 2026, its #17 holding.
  • SoftBank Group first reported a position in Pacific Biosciences in Q4 2024 and has held it in 7 quarters since.
  • SoftBank Group's Pacific Biosciences position peaked at $38.2M in Q4 2025.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on SoftBank Group's 13F filing for Q2 2026, filed 14 Aug 2026.